about
[Adjuvant radiochemotherapy in the elderly affected by glioblastoma: single-institution experience and literature review].Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.Elderly patients affected by glioblastoma treated with radiotherapy: the role of serum hemoglobin level.Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.Parotid gland volumetric changes during intensity-modulated radiotherapy in head and neck cancerCorrelation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma.The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literature.Radiotherapy and bevacizumab for intramedullary and leptomenigeal metastatic glioblastoma: a case report and review of the literature.Elderly patients with glioblastoma: the treatment challenge.From radiobiology to technology: what is changing in radiotherapy for prostate cancer.Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era.Radiation dose intensification in pre-operative chemo-radiotherapy for locally advanced rectal cancer.Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature.Intensity modulated radiation therapy with simultaneous integrated boost in early breast cancer irradiation. Report of feasibility and preliminary toxicity.Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response.Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.Head and neck intensity modulated radiotherapy parotid glands: time of re-planning.Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma.Impact of machines on plan quality: volumetric modulated arc therapy and intensity modulated radiation therapy.Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands.Low-dose rate brachytherapy of the prostate in elderly patients.Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes.Clinical target volume definition for glioblastoma radiotherapy planning: magnetic resonance imaging and computed tomography.Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.The intriguing issue of genetic predisposition and the importance of identification of pre-clinical markers of endothelial damage in radiotherapy-induced cardiotoxicity.Volumetric and dosimetric assessment by cone-beam computed tomography scans in head and neck radiation therapy: a monitoring in four phases of treatment.Critical dose and toxicity index of organs at risk in radiotherapy: analyzing the calculated effects of modified dose fractionation in non-small cell lung cancer.Planning target volume assessment in lung tumors during 3D conformal radiotherapy by means of an aSi electronic portal imaging device in cine mode.Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy: A consensus document from Associazione Italiana Aritmologia e Cardiostimolazione (AIAC), Associazione Italiana Radioterapia Oncologica (AIRO), AssociaThe influence of surgery on recurrence pattern of glioblastoma.Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study.Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?Regarding Ening et al. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification.The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma.Technique of whole brain radiotherapy: conformity index and parotid glands.Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma."Whole brain radiotherapy: are parotid glands organs at risk?".18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes.
P50
Q33404566-47CE0C23-4013-4792-B3F0-FA85790D1B05Q34295064-70EE649F-435A-453A-881F-A2D961963F89Q34461414-E047EF1B-DB6E-4049-9288-8BED6DED9246Q35633819-FC5F4F4C-69B2-415A-9262-2BA02D96E0CCQ36325935-46667F67-2C3A-4609-9631-EEE3C92688F8Q36510348-CD47781C-6C41-4C44-92D2-C238615C9A4BQ37909180-2E6C2626-496A-424C-BFA9-1EAB659B2A35Q38020534-C247EEE0-FAB5-4774-BF72-894068E28CC5Q38151772-D8F5CD9C-14E1-45D5-ABFE-9FC7340A131DQ38191990-AD6CF7DD-2514-4C76-B815-971B5676D19AQ38280403-97B49768-9718-4EDE-AEC0-75CC398322DDQ38857880-1DEDBDF8-4B41-480C-AC4D-505E97FAC00FQ38942326-983AA1D1-D4C6-4642-AC60-369D22522FD4Q39191284-BCD1D1F2-1885-4805-A9E1-7DB3BE1114E3Q40701137-301FC34A-04D9-4C7F-9F0D-537CED457650Q42116312-0889C9F6-571C-4543-8C02-CF24D7CE9640Q42862815-E38B378B-8205-41A4-BEDF-D5D26BB63D1FQ43286608-5000A3BC-30CD-4AD2-A24A-87FA5DC032A3Q43428842-0FA53874-5C6F-40EA-AA78-AA087889348FQ43795420-FE3A3C5F-7E49-447D-8094-31660F7C59E4Q43812289-F3A63581-8336-41C6-AF1E-CE781A47A8BDQ44196406-0D1AC547-3578-484F-A707-682D860F6366Q44415409-C6C5CEC7-85FE-4FB6-9B31-8A180879C578Q45126380-64A3D395-59DC-4528-85C2-B1DBC8CCCBC6Q45366165-6EA00005-241B-4879-94A7-3563C4167A65Q45399501-2511F788-AFCE-4CB2-A14E-8A70C511F79CQ45416187-3A84C902-9EA9-4275-AC39-922BBCB4D358Q45720741-04B155C0-3E42-42A7-B8B6-C3110A786F63Q45838746-5E0C0606-A0B5-44CC-BBE6-0A4FA87B14D1Q46057932-489CBDA7-2337-447A-B762-7F3073BC3396Q47193349-893D7FAB-FF94-4349-A9B7-26FBA9C8A02DQ47846309-D6AA735F-E12C-4D3E-B71A-73D082D14CA0Q48095675-41691B26-9ACF-4259-8831-CC98683C61AFQ48173544-6431D51E-E367-4E91-A5D9-7407F9EA546AQ48311803-61C07417-77EA-4012-8A3D-19DC7D78F164Q48384940-0BC811D1-17E1-4AF1-ABE5-EEC648A13101Q48426183-1105BA60-8300-4C7C-8E52-B9B1FE3775DCQ48465999-5A4A3ABD-C4B0-4631-9D1D-3EA6BF7373F1Q48631188-A3FEC03A-89CF-47B0-9B22-EFC1C16666F9Q48679846-8ECF0B99-1311-41C2-82C8-EB263A2316E4
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alba Fiorentino
@ast
Alba Fiorentino
@en
Alba Fiorentino
@es
Alba Fiorentino
@nl
type
label
Alba Fiorentino
@ast
Alba Fiorentino
@en
Alba Fiorentino
@es
Alba Fiorentino
@nl
prefLabel
Alba Fiorentino
@ast
Alba Fiorentino
@en
Alba Fiorentino
@es
Alba Fiorentino
@nl
P106
P1153
7005112098
P21
P31
P496
0000-0003-4201-5852